Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | KIF11 | P52732 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.54 |
| ▸ | ARNT | P27540 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646781 | 0.91 | AKR1B1 (0.70) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL4605709 | 0.89 | MAPK1 (0.59) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL7167600 | 0.85 | TDP1 (0.79) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL8559386 | 0.84 | AKR1B1 (0.77) | MAPK1ALDH1A1L3MBTL1KIF11AKR1B1 | |
| SCHEMBL25782133 | 0.84 | MAPK1 (0.68) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL29824482 | 0.84 | MAPK1 (0.68) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL21959051 | 0.83 | AKR1C3 (0.56) | MAPK1ALDH1A1L3MBTL1KIF11AKR1B1 | |
| SCHEMBL26468007 | 0.83 | TDP1 (0.77) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 | |
| SCHEMBL21856334 | 0.81 | MAPK1 (0.61) | MAPK1ALDH1A1L3MBTL1KIF11AKR1B1 | |
| SCHEMBL6655634 | 0.81 | AKR1B1 (0.56) | MAPK1ALDH1A1TDP1L3MBTL1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| CN-101600701-A | Arylsulfonamide derivatives and methods of use thereof | WYETH CORP (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| US-4510141-A | (1,2,4) TRIAZOLO(1,5-A) QUINOXALINE OR PYRIDO(2,3-E)(U,2,4)TRIAZOLO(1,5-A)PYRAZINE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0074929-A1 | Polycyclic polyazaheterocycles, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MAPK1 1634/4885ALDH1A1 687/4885TDP1 367/4885 |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | MAPK1 3029/4885ALDH1A1 2662/4885TDP1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.